{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:51:12Z","timestamp":1793994672605,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frankfurt School of Finance & Management gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Anemia Control Model (ACM) is a decision support system powered by an artificial intelligence core designed to assist nephrologists in managing anemia therapy for in-center hemodialysis (HD) patients. This study aims to evaluate the cost-effectiveness of the ACM compared to standard of care in Germany, defined as the absence of ACM and a hemoglobin (Hb) target achievement rate of less than 70% among in-center HD patients, based on results from matched observational studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This simulation study adopted the perspective of the German statutory health insurance. A Markov (cohort) state-transition model was used to project the effects of the ACM over the remaining lifetime of patients. All costs were expressed in 2024 euros, and both costs and quality-adjusted life years (QALYs) were discounted at a rate of 3% per year. To test the sensitivity of the results, one-way sensitivity analyses and a probabilistic sensitivity analysis were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study finds that ACM provides more QALYs and incurs lower costs compared to standard of care. The net monetary value of ACM is \u20ac38,423 per patient in the base case scenario. In the sensitivity analysis, the annual cost of erythropoiesis-stimulating agents emerged as the variable with the largest impact on the value of ACM. The probabilistic sensitivity analysis shows that 100% of cost-effect pairs fall within the dominant southeast quadrant, indicating cost-effectiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This modelling study demonstrates that ACM is cost-effective for managing anemia in German in-center HD patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04298-7","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:37:43Z","timestamp":1756377463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Health-economic evaluation of an AI-powered decision support system for anemia management in in-center hemodialysis patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Afschin","family":"Gandjour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Apel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Kendzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Usvyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Petrovic Vorkapic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"4298_CR1","unstructured":"Kalis B, Collier M, Fu R. 10 Promising AI Applications in Health Care. May 10. 2018. https:\/\/hbr.org\/2018\/05\/10-promising-ai-applications-in-health-care"},{"issue":"1","key":"4298_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/sdi.12915","volume":"34","author":"S Chaudhuri","year":"2021","unstructured":"Chaudhuri S, Long A, Zhang H, Monaghan C, Larkin JW, Kotanko P, Kalaskar S, Kooman JP, van der Sande FM, Maddux FW, Usvyat LA. Artificial intelligence enabled applications in kidney disease. Semin Dial. 2021;34(1):5\u201316.","journal-title":"Semin Dial"},{"issue":"6","key":"4298_CR3","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1159\/000495818","volume":"43","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhang Y, Liu D, Tan X, Tang X, Zhang F, Xia M, Chen G, He L, Zhou L, Zhu X, Liu H. Prediction of ESRD in IgA nephropathy patients from an Asian cohort: a random forest model. Kidney Blood Press Res. 2018;43(6):1852\u201364.","journal-title":"Kidney Blood Press Res"},{"key":"4298_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO CKD Work Group","year":"2013","unstructured":"KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"4298_CR5","unstructured":"Macdougall IC, Eckardt KU. Anemia in chronic kidney disease. In: Johnson RJ, Feehally J, Floege J, editors. Comprehensive Clinical Nephrology e-Book. Elsevier Health Sciences; 2014."},{"issue":"2","key":"4298_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.kint.2016.03.036","volume":"90","author":"C Barbieri","year":"2016","unstructured":"Barbieri C, Molina M, Ponce P, Tothova M, Cattinelli I, Ion Titapiccolo J, Mari F, Amato C, Leipold F, Wehmeyer W, Stuard S, Stopper A, Canaud B. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients. Kidney Int. 2016;90(2):422\u20139.","journal-title":"Kidney Int"},{"issue":"2","key":"4298_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.09960911","volume":"7","author":"BJ Manns","year":"2012","unstructured":"Manns BJ, Tonelli M. The new FDA labeling for ESA\u2013implications for patients and providers. Clin J Am Soc Nephrol. 2012;7(2):348\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4298_CR8","unstructured":"Renal Association. Clinical practice guideline on anaemia of chronic kidney disease. Updated February 2020. https:\/\/ukkidney.org\/sites\/renal.org\/files\/Updated-130220-Anaemia-of-Chronic-Kidney-Disease-1-1.pdf"},{"key":"4298_CR9","doi-asserted-by":"crossref","unstructured":"Bucalo ML, Barbieri C, Roca S, Ion Titapiccolo J, Ros Romero MS, Ramos R, Albaladejo M, Manzano D, Mari F, Molina M. The anaemia control model: does it help nephrologists in therapeutic decision-making in the management of anaemia? Nefrologia (Engl Ed). 2018 Sep-Oct;38(5):491\u2013502.","DOI":"10.1016\/j.nefroe.2018.10.001"},{"issue":"5","key":"4298_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000536181","volume":"53","author":"M Garbelli","year":"2024","unstructured":"Garbelli M, Bellocchio F, Baro Salvador ME, Chermisi M, Rincon Bello A, Godoy IB, Perez SO, Shkolenko K, Perez AS, Toro DS, Apel C, Petrovic J, Stuard S, Barbieri C, Mari F, Neri L. The use of anemia control model is associated with improved hemoglobin target achievement, lower rates of inappropriate erythropoietin stimulating agents, and severe anemia among dialysis patients. Blood Purif. 2024;53(5):405\u201317.","journal-title":"Blood Purif"},{"issue":"1","key":"4298_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000442741","volume":"42","author":"L Zuo","year":"2016","unstructured":"Zuo L, Wang M, Hou F, Yan Y, Chen N, Qian J, Wang M, Bieber B, Pisoni RL, Robinson BM, Anand S. Anemia management in the China Dialysis Outcomes and Practice Patterns Study. Blood Purif. 2016;42(1):33\u201343.","journal-title":"Blood Purif"},{"issue":"4","key":"4298_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5414\/CN109499","volume":"90","author":"AE Gaweda","year":"2018","unstructured":"Gaweda AE, Jacobs AA, Aronoff GR, Brier ME. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience. Clin Nephrol. 2018;90(4):276\u201385.","journal-title":"Clin Nephrol"},{"key":"4298_CR13","unstructured":"United States Renal Data System. 2017 Annual data report. https:\/\/www.usrds.org\/media\/2286\/2017_volume_2_esrd_in_the_us.pdf"},{"issue":"10","key":"4298_CR14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3390\/biomedicines12102219","volume":"12","author":"M Garbelli","year":"2024","unstructured":"Garbelli M, Baro Salvador ME, Rincon Bello A, Samaniego Toro D, Bellocchio F, Fumagalli L, Chermisi M, Apel C, Petrovic J, Kendzia D, et al. Usage of the Anemia control model is associated with reduced hospitalization risk in hemodialysis. Biomedicines. 2024;12(10):2219.","journal-title":"Biomedicines"},{"key":"4298_CR15","doi-asserted-by":"crossref","unstructured":"H\u00e4ckl D, Kossack N, Schoenfelder T. Pr\u00e4valenz, Kosten der Versorgung und Formen des dialysepflichtigen chronischen Nierenversagens in Deutschland: Vergleich der Dialyseversorgung innerhalb und au\u00dferhalb station\u00e4rer Pflegeeinrichtungen. Gesundheitswesen. 2021;83(10):818\u201328.","DOI":"10.1055\/a-1330-7152"},{"key":"4298_CR16","unstructured":"Bundesgesundheitsministerium. Februar. Ergebnisse der GKV-Statistik KM1. Stand: Februar 2022. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_Januar_bis_Februar_2022_bf.pdf"},{"key":"4298_CR17","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Einheitlicher Bewertungsma\u00dfstab. Stand 2022\/1."},{"key":"4298_CR18","doi-asserted-by":"crossref","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998 Apr-Jun;18(2 Suppl):S68\u201380.","DOI":"10.1177\/0272989X98018002S09"},{"key":"4298_CR19","volume-title":"Wirtschaftlichkeit Im gesundheitswesen. General methods. Version 7.0","author":"Institut f\u00fcr Qualit\u00e4t und","year":"2023","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General methods. Version 7.0. K\u00f6ln: IQWiG; 2023."},{"key":"4298_CR20","first-page":"e067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.","journal-title":"Health Economic Evaluations BMJ"},{"key":"4298_CR21","unstructured":"Registry ERA-EDTA: ERA-EDTA Registry Annual Report 2019., Amsterdam UMC. location AMC, Department of Medical Informatics, Amsterdam, the Netherlands, 2021."},{"key":"4298_CR22","volume-title":"Sterbetafeln 2018\/2020","author":"Statistisches Bundesamt","year":"2021","unstructured":"Statistisches Bundesamt. Sterbetafeln 2018\/2020. Wiesbaden: Statistisches Bundesamt; 2021."},{"issue":"4","key":"4298_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/0272989X09340585","volume":"29","author":"JJ Barendregt","year":"2009","unstructured":"Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Mak. 2009;29(4):500\u20132.","journal-title":"Med Decis Mak"},{"issue":"2","key":"4298_CR30","first-page":"CD010590","volume":"2","author":"EY Chung","year":"2023","unstructured":"Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):CD010590.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4298_CR31","doi-asserted-by":"publisher","first-page":"e0169400","DOI":"10.1371\/journal.pone.0169400","volume":"12","author":"O K\u00f6nigsbr\u00fcgge","year":"2017","unstructured":"K\u00f6nigsbr\u00fcgge O, Posch F, Antlanger M, Kovarik J, Klauser-Braun R, Kletzmayr J, Schmaldienst S, Auinger M, Zuntner G, Lorenz M, Grilz E, Stampfel G, Steiner S, Pabinger I, S\u00e4emann M, Ay C. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PLoS ONE. 2017;12(1):e0169400.","journal-title":"PLoS ONE"},{"issue":"9","key":"4298_CR32","doi-asserted-by":"publisher","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","volume":"9","author":"M Wyld","year":"2012","unstructured":"Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.","journal-title":"PLoS Med"},{"issue":"1","key":"4298_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88.","journal-title":"BMC Nephrol"},{"key":"4298_CR36","unstructured":"Gemeinsamer Bundesausschuss. Vadadustat (symptomatische An\u00e4mie bei chronischer Nierenerkrankung (CKD)). Beschluss vom 22. November 2024. https:\/\/www.g-ba.de\/downloads\/91-1385-1091\/2024-11-22_Geltende-Fassung_Vadadustat_D-1073.pdf"},{"key":"4298_CR29","unstructured":"AOK. Der errechnete Bundesbasisfallwert. https:\/\/www.aok.de\/gp\/verwaltung\/landesbasisfallwerte\/bundesbasisfallwert"},{"key":"4298_CR28","unstructured":"Gemeinsamer Bundesausschuss. Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie: Anlage XII\u2013 Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a des F\u00fcnften Buches Sozialgesetzbuch (SGB V) Mavacamten (symptomatische hypertrophe obstruktive Kardiomyopathie (NYHA Klasse II\u2013III)) Vom 1. Februar 2024. https:\/\/www.g-ba.de\/downloads\/40-268-10197\/2024-02-01_AM-RL-XII_Mavacamten_D-962_TrG.pdf"},{"key":"4298_CR37","unstructured":"KBV, Kassen\u00e4rztliche Bundesvereinigung. Einheitlicher Bewertungsma\u00dfstab (EBM). Stand: 2. Quartal 2025. https:\/\/www.kbv.de\/media\/sp\/EBM_Gesamt_-_Stand_2._Quartal_2025.pdf"},{"key":"4298_CR24","unstructured":"Institut f\u00fcr Qualit\u00e4tssicherung und Transparenz im Gesundheitswesen. Beschreibung der Qualit\u00e4tsindikatoren und Kennzahlen nach DeQS-RL. Nierenersatztherapie bei chronischem Nierenversagen einschlie\u00dflich Pankreastransplantationen: Dialyse. Prospektive Rechenregeln f\u00fcr das Erfassungsjahr 2021. Berlin: IQTIG; 17.12.2020."},{"key":"4298_CR25","unstructured":"United States Renal Data System. 2018 USRDS Annual Data Report. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.usrds.org%2Fmedia%2F1787%2Fv2_c02_clincare_18_slides.pptxwdOrigin=BROWSELINK"},{"issue":"9596","key":"4298_CR26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"4","key":"4298_CR27","doi-asserted-by":"publisher","first-page":"e0231375","DOI":"10.1371\/journal.pone.0231375","volume":"15","author":"A Gandjour","year":"2020","unstructured":"Gandjour A, Armsen W, Wehmeyer W, Multmeier J, Tschulena U. Costs of patients with chronic kidney disease in Germany. PLoS ONE. 2020;15(4):e0231375.","journal-title":"PLoS ONE"},{"key":"4298_CR34","unstructured":"Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in der Bundesrepublik Deutschland. Routinedatenauswertung zu H\u00e4mo- versus Peritonealdialysen in Deutschland. 28.05.2019. https:\/\/www.zi.de\/fileadmin\/images\/content\/Projekte\/MAUPD_Abschlussbericht_Zi_final.pdf"},{"issue":"6","key":"4298_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40258-015-0179-0","volume":"13","author":"R L\u00e9vesque","year":"2015","unstructured":"L\u00e9vesque R, Marcelli D, Cardinal H, Caron ML, Grooteman MP, Bots ML, Blankestijn PJ, Nub\u00e9 MJ, Grassmann A, Canaud B, Gandjour A. Cost-effectiveness analysis of high-efficiency hemodiafiltration versus low-flux hemodialysis based on the Canadian arm of the CONTRAST study. Appl Health Econ Health Policy. 2015;13(6):647\u201359.","journal-title":"Appl Health Econ Health Policy"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04298-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04298-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:59:14Z","timestamp":1757447954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04298-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4298"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04298-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study, as it utilized publicly available data and did not involve direct patient or human subject participation. Informed consent was not applicable for the same reason. The study was conducted in accordance with the principles of the Declaration of Helsinki and followed established methodological guidelines for economic evaluations, including the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Christian Apel, Dana Kendzia, Luca Neri, Francesco Bellocchio, Len Usvyat, John Larkin, and Jovana Petrovic are full time employees at Fresenius Medical Care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}